Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Change in Account Payables (2023 - 2025)

Historic Change in Account Payables for Artiva Biotherapeutics (ARTV) over the last 3 years, with Q3 2025 value amounting to -$442000.0.

  • Artiva Biotherapeutics' Change in Account Payables fell 16278.41% to -$442000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$692000.0, marking a year-over-year increase of 4761.54%. This contributed to the annual value of $519000.0 for FY2024, which is 22720.59% up from last year.
  • Latest data reveals that Artiva Biotherapeutics reported Change in Account Payables of -$442000.0 as of Q3 2025, which was down 16278.41% from -$209000.0 recorded in Q2 2025.
  • Artiva Biotherapeutics' 5-year Change in Account Payables high stood at $1.6 million for Q3 2023, and its period low was -$1.9 million during Q4 2023.
  • Moreover, its 3-year median value for Change in Account Payables was -$82000.0 (2024), whereas its average is -$47444.4.
  • In the last 5 years, Artiva Biotherapeutics' Change in Account Payables skyrocketed by 9573.36% in 2024 and then tumbled by 16278.41% in 2025.
  • Artiva Biotherapeutics' Change in Account Payables (Quarter) stood at -$1.9 million in 2023, then soared by 95.73% to -$82000.0 in 2024, then plummeted by 439.02% to -$442000.0 in 2025.
  • Its Change in Account Payables was -$442000.0 in Q3 2025, compared to -$209000.0 in Q2 2025 and $41000.0 in Q1 2025.